U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

TOKYO, Japan - Dainippon Sumitomo Pharma Co. President Masayo Tada speaks about the company's plan to buy U.S. pharmaceutical maker Sepracor Inc. for about $2.6 billion (around 240 billion yen) at a news conference in Tokyo on Sept. 3. Sepracor will become a wholly owned unit of Dainippon Sumitomo Pharma America Holdings Inc., a U.S. subsidiary of the Japanese drugmaker.

Dainippon Sumitomo to buy out U.S. drugmaker Sepracor

Dainippon Sumitomo to buy out U.S. drugmaker Sepracor

OSAKA, Japan - Photo taken Sept. 3 shows the headquarters of Dainippon Sumitomo Pharma Co. in Osaka. The company said the same day it has agreed to buy out Sepracor Inc., a Massachusetts-based pharmaceutical maker, for around $2.6 billion in an attempt to tap into the U.S. market.

1st batch of Moderna COVID-19 vaccine arrives in Japan

OSAKA, April 30 Kyodo - The first batch of the coronavirus vaccine developed by U.S. pharmaceutical maker Moderna Inc. arrived in Japan on Friday, with the government planning to use it at mass vaccination centers following expected approval in May.It will become the second type of shot available in the country after the one developed by Pfizer Inc. if a health ministry panel gives it the green light, possibly by May 20. The Moderna vaccine that arrived at Kansai airport in Osaka Prefecture from Belgium is expected to be used at large-scale COVID-19 vaccination centers that the central government plans to open in Tokyo and Osaka, according to the government.

Japan generic drug maker Nichi-Iko to acquire Sagent of U.S.

Japan generic drug maker Nichi-Iko to acquire Sagent of U.S.

Yuichi Tamura, president of generic drug company Nichi-Iko Pharmaceutical Co., has a press conference in Toyama, Japan, on July 11, 2016. Nichi-Iko will acquire U.S. generic drug maker Sagent Pharmaceuticals Inc. for roughly $736 million in a bid to expand its presence in the U.S. market. (Kyodo) ==Kyodo

Takeda to buy U.S. cancer drug maker ARIAD Pharmaceuticals

Takeda to buy U.S. cancer drug maker ARIAD Pharmaceuticals

File photo taken in October 2010 shows the Tokyo headquarters of Takeda Pharmaceutical Co. The firm said on Jan. 9, 2017, that it will buy Massachusetts-based ARIAD Pharmaceuticals Inc. in a deal valued at $5.2 billion to expand its cancer treatment business. (Kyodo) ==Kyodo

Konica Minolta to buy U.S. drug research company for 32 bil. yen

Konica Minolta to buy U.S. drug research company for 32 bil. yen

Konica Minolta Inc. President Shoei Yamana speaks at a press conference in Tokyo on Sept. 25, 2017. The Japanese maker of copiers, printers and precision equipment will acquire U.S. pharmaceutical research company Invicro LLC for roughly 32 billion yen ($284 million) in a bid to enhance its medical-related operations. (Kyodo) ==Kyodo

Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

TOKYO, Japan - Dainippon Sumitomo Pharma Co. President Masayo Tada speaks about the company's plan to buy U.S. pharmaceutical maker Sepracor Inc. for about $2.6 billion (around 240 billion yen) at a news conference in Tokyo on Sept. 3. Sepracor will become a wholly owned unit of Dainippon Sumitomo Pharma America Holdings Inc., a U.S. subsidiary of the Japanese drugmaker. (Kyodo)

Dainippon Sumitomo to buy out U.S. drugmaker Sepracor

Dainippon Sumitomo to buy out U.S. drugmaker Sepracor

OSAKA, Japan - Photo taken Sept. 3 shows the headquarters of Dainippon Sumitomo Pharma Co. in Osaka. The company said the same day it has agreed to buy out Sepracor Inc., a Massachusetts-based pharmaceutical maker, for around $2.6 billion in an attempt to tap into the U.S. market. (Kyodo)